Renaissance Washington DC Downtown Hotel , Washington, DC, USA
Mar 14 2012 8:00AM - Mar 15 2012 5:00PM
This meeting will highlight the changing nature of evidence standards within the marketplace; specifi cally, the continued push for increased levels of evidence of comparative eff ectiveness applied within health technology assessments (HTAs). The goal of the meeting is to focus less on defi nitions and theoretic concepts, and more on the application of comparative eff ectiveness research (CER) and HTA within drug development and research planning. While the discussion of CER has been ongoing for years, the recent creation of the Patient-Centered Outcomes Research Institute (PCORI) within health care reform, as well as new standards for evidence evaluation development by leading payers, have made understanding not just the theories, but rather their applications, of vital importance. This meeting will push beyond the basic questions to evaluate the importance of CER and provide participants with actionable understandings of how CER evidence can be better managed and developed within their own organizations. Unlike previous eff orts in this area, this meeting will provide participants with a “what does it mean for me” perspective on CER and HTA, providing take-aways to apply within day-to-day drug development and marketing positions. Event Code:
12027
|